Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
772.700.06%
QQQ
717.030.09%
BTC/USD
81062.500.2628%
DIA
536.820.02%
GLD
410.870.16%
TLT
82.140.09%

Cue Biopharma Inc

CUENASDAQ
Trade with Public
Trade with Public
$27.67
0.712.63%
At close: Sep 3, 5:00 PM EST
$26.99
-0.68-2.46%
After Hours: 8:28 AM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Cue Biopharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for Cue Biopharma (CUE).

Price Target Range — 6 Quarters

Analyst Consensus — 7 Analysts

2S.Buy
5Buy
Consensus RatingBuy# Analysts7Avg. Consensus PT$4Upside to Avg. PT-83.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 25, 2025LUCID CAPITAL MARKETSDev Prasad InitiateBuy$4
Apr 2, 2025Citizens Capital MarketsReni BenjaminMaintainedMarket Outperform$2
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
LUCID CAPITAL MARKETS Initiates Coverage On Cue Biopharma with Buy Rating, Announces Price Target of $4

LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on Cue Biopharma (NASDAQ:CUE) with a Buy rating and announces Price Target of $4.
Benzinga Newsdesk

PRO
Citizens Capital Markets Reiterates Market Outperform on Cue Biopharma, Maintains $2 Price Target

Citizens Capital Markets analyst Reni Benjamin reiterates Cue Biopharma (NASDAQ:CUE) with a Market Outperform and maintains $2 price target.
Benzinga Newsdesk

PRO
Stifel Maintains Buy on Cue Biopharma, Lowers Price Target to $4

Stifel analyst Stephen Willey maintains Cue Biopharma (NASDAQ:CUE) with a Buy and lowers the price target from $8 to $4.
Benzinga Newsdesk

Cue Biopharma, Inc. Reports Q2 Loss, Tops Revenue Estimates

Cue Biopharma, Inc. (NASDAQ: CUE) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.29 per share a year ago. These figures are adjusted for non-recurring items.
Zacks

PRO
JMP Securities Maintains Market Outperform on Cue Biopharma, Lowers Price Target to $2

JMP Securities analyst Reni Benjamin maintains Cue Biopharma (NASDAQ:CUE) with a Market Outperform and lowers the price target from $15 to $2.
Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on Cue Biopharma, Lowers Price Target to $3

Piper Sandler analyst Edward Tenthoff maintains Cue Biopharma (NASDAQ:CUE) with a Overweight and lowers the price target from $8 to $3.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved